ADMET findings indicate that Withametelin B, Candidine, Jervine, and Delavinone possess drug-like properties and non-toxic features and should proceed to the next stage of the screening cascade as ULK1 activators relevant to ALS therapeutics. Here, ULK1 is linked to amyotrophic lateral sclerosis.